Ovid Therapeutics (OVID) is experiencing a significant shift in market positioning as it approaches its November 13 earnings print. Short interest, while still high at 23.2% of the free float, has dropped by approximately 33% over the past month, falling from 26 million shares to 16.5 million. This rapid cover coincides with a 19% weekly gain in the stock price. Borrow conditions are currently loose, with availability at 227% and a negligible cost to borrow of 0.70%. This indicates that the reduction in short interest is driven by a genuine reassessment of clinical risk rather than a forced squeeze. The upcoming earnings will determine if the pipeline data flow can sustain the current bullish momentum.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.